HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

An in vitro deletion in ribE encoding lumazine synthase contributes to nitrofurantoin resistance in Escherichia coli.

Abstract
Nitrofurantoin has been used for decades for the treatment of urinary tract infections (UTIs), but clinically significant resistance in Escherichia coli is uncommon. Nitrofurantoin concentrations in the gastrointestinal tract tend to be low, which might facilitate selection of nitrofurantoin-resistant (NIT-R) strains in the gut flora. We subjected two nitrofurantoin-susceptible intestinal E. coli strains (ST540-p and ST2747-p) to increasing nitrofurantoin concentrations under aerobic and anaerobic conditions. Whole-genome sequencing was performed for both susceptible isolates and selected mutants that exhibited the highest nitrofurantoin resistance levels aerobically (ST540-a and ST2747-a) and anaerobically (ST540-an and ST2747-an). ST540-a/ST540-an and ST2747-a (aerobic MICs of >64 μg/ml) harbored mutations in the known nitrofurantoin resistance determinants nfsA and/or nfsB, which encode oxygen-insensitive nitroreductases. ST2747-an showed reduced nitrofurantoin susceptibility (aerobic MIC of 32 μg/ml) and exhibited remarkable growth deficits but did not harbor nfsA/nfsB mutations. We identified a 12-nucleotide deletion in ribE, encoding lumazine synthase, an essential enzyme involved in the biosynthesis of flavin mononucleotide (FMN), which is an important cofactor for NfsA and NfsB. Complementing ST2747-an with a functional wild-type lumazine synthase restored nitrofurantoin susceptibility. Six NIT-R E. coli isolates (NRCI-1 to NRCI-6) from stools of UTI patients treated with nitrofurantoin, cefuroxime, or a fluoroquinolone harbored mutations in nfsA and/or nfsB but not ribE. Sequencing of the ribE gene in six intestinal and three urinary E. coli strains showing reduced nitrofurantoin susceptibility (MICs of 16 to 48 μg/ml) also did not identify any relevant mutations. NRCI-1, NRCI-2, and NRCI-5 exhibited up to 4-fold higher anaerobic MICs, compared to the mutants generated in vitro, presumably because of additional mutations in oxygen-sensitive nitroreductases.
AuthorsJascha Vervoort, Basil Britto Xavier, Andrew Stewardson, Samuel Coenen, Maciek Godycki-Cwirko, Niels Adriaenssens, Anna Kowalczyk, Christine Lammens, Stephan Harbarth, Herman Goossens, Surbhi Malhotra-Kumar
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 58 Issue 12 Pg. 7225-33 (Dec 2014) ISSN: 1098-6596 [Electronic] United States
PMID25246406 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014, American Society for Microbiology. All Rights Reserved.
Chemical References
  • Anti-Bacterial Agents
  • Escherichia coli Proteins
  • Fluoroquinolones
  • Multienzyme Complexes
  • 6,7-dimethyl-8-ribityllumazine synthase
  • Nitrofurantoin
  • NfsA protein, E coli
  • NfsB protein, E coli
  • Nitroreductases
  • Riboflavin Synthase
  • Cefuroxime
Topics
  • Aerobiosis
  • Anaerobiosis
  • Anti-Bacterial Agents (pharmacology)
  • Base Sequence
  • Cefuroxime (pharmacology)
  • Drug Resistance, Bacterial (genetics)
  • Escherichia coli (drug effects, enzymology, genetics, isolation & purification)
  • Escherichia coli Infections (drug therapy, microbiology)
  • Escherichia coli Proteins (genetics, metabolism)
  • Fluoroquinolones (pharmacology)
  • Genetic Complementation Test
  • Humans
  • Microbial Sensitivity Tests
  • Molecular Sequence Data
  • Multienzyme Complexes (genetics, metabolism)
  • Nitrofurantoin (pharmacology)
  • Nitroreductases (genetics, metabolism)
  • Riboflavin Synthase (genetics, metabolism)
  • Sequence Deletion
  • Urinary Tract Infections (drug therapy, microbiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: